Repatha® Outcomes Study (FOURIER): Subgroup and landmark analyses
header logo

Terms of Use

The information contained on this site is for healthcare professionals only.

I am a healthcare professional from
Choose a Country ▼

REPATHA®
APPROVED TO
REDUCE
CARDIOVASCULAR
RISK1

Repatha® Outcomes Study (FOURIER): Subgroup and landmark analyses

  • Repatha® delivered significant CV risk reductions across key patient subgroups, including patients with a recent MI2-7
  • With Repatha®, the majority of recent MI patients achieved LDL-C goals2
  • CV risk reduction with Repatha® extended down to LDL-C levels as low as <10 mg/dl, with no evidence of a plateau8
  • Landmark analyses demonstrate that CV risk reduction with Repatha® increased with longer duration of treatment9

*In the study, 2690 recent MI patients received Repatha®, 2254 of whom achieved LDL-C levels <55 mg/dl.
25% RRR reported as the key secondary endpoint: composite of cardiovascular death, MI or stroke. HR: 0.75; 95% CI: 0.62-0.91; p=0.003. ARR: 3.2%; 95% CI: 1.2-5.2.
ACS = Acute coronary syndrome; ARR = Absolute risk reduction; CV = Cardiovascular; EAS = European Atherosclerosis Society; ESC = European Society of Cardiology; EVOPACS = EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes; FOURIER = Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk; LDL-C = Low-density lipoprotein cholesterol; MI = Myocardial infarction; PAD = Peripheral artery disease; PCSK9 = Protein convertase subtilisin/kexin type 9; RRR = Relative risk reduction.
  1. Repatha® (evolocumab) Summary of Product Characteristics. Last revised: April 2020.
  2. Gencer B, et al. JAMA Cardiol. 2020; Online first. doi:10.1001/jamacardio.2020.0882.
  3. Sabatine MS, et al. Circulation. 2018;138:756-66.
  4. Pedersen TR. FOURIER (Further cardiovascular Outcomes Research with PCSK9 Inhibition in subjects with Elevated Risk). Focus on Cerebrovascular Disease. European Society of Cardiology Congress 2017. Late-Breaking Clinical Trial presented August 29, 2017.
  5. Sabatine MS, et al. Lancet Diabetes Endocrinol. 2017;5:941-50 & Supplementary Appendix.
  6. Bonaca MP, et al. Circulation. 2018;137:338-50.
  7. Charytan DM, et al. J Am Coll Cardiol. 2019;73:2961-270.
  8. Giugliano RP, et al. Lancet. 2017;390:1962-71.
  9. Sabatine MS, et al. N Engl J Med. 2017;376:1713-22. Supplementary Appendix.

By clicking the 'DOWNLOAD' button below you will immediately begin downloading the Reporting Systems Appendix
Return to previous page DOWNLOAD